PTC Therapeutics Inc
NASDAQ:PTCT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
36.19
86.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
PTCT
stock under the Base Case scenario is
62.38
USD.
Compared to the current market price of 78.37 USD,
PTC Therapeutics Inc
is
Overvalued by 20%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for PTC Therapeutics Inc.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
PTC Therapeutics Inc
Balance Sheet Decomposition
PTC Therapeutics Inc
| Current Assets | 2B |
| Cash & Short-Term Investments | 1.7B |
| Receivables | 203.1m |
| Other Current Assets | 116.9m |
| Non-Current Assets | 635.9m |
| PP&E | 137.7m |
| Intangibles | 478.8m |
| Other Non-Current Assets | 19.4m |
| Current Liabilities | 866.2m |
| Accounts Payable | 91.9m |
| Accrued Liabilities | 98.6m |
| Other Current Liabilities | 675.7m |
| Non-Current Liabilities | 1.9B |
| Long-Term Debt | 1.8B |
| Other Non-Current Liabilities | 98.1m |
Free Cash Flow Analysis
PTC Therapeutics Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
PTC Therapeutics Inc
|
Revenue
|
1.8B
USD
|
|
Cost of Revenue
|
-56.3m
USD
|
|
Gross Profit
|
1.7B
USD
|
|
Operating Expenses
|
-789.6m
USD
|
|
Operating Income
|
933.2m
USD
|
|
Other Expenses
|
-181.5m
USD
|
|
Net Income
|
751.7m
USD
|
PTCT Profitability Score
Profitability Due Diligence
PTC Therapeutics Inc's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
PTC Therapeutics Inc's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
PTCT Solvency Score
Solvency Due Diligence
PTC Therapeutics Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
PTC Therapeutics Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PTCT Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
PTCT
is 83.37 USD
with a low forecast of 55.55 USD and a high forecast of 123.9 USD.
Dividends
Current shareholder yield for
PTCT is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
PTCT
stock under the Base Case scenario is
62.38
USD.
Compared to the current market price of 78.37 USD,
PTC Therapeutics Inc
is
Overvalued by 20%.